Adjuvant simultaneous treatment with mistletoe during chemotherapy for breast cancer - Influence on immune parameters, quality of life and tolerability;Adjuvante simultane mistel-/chemotherapie bei mammakarzinom - Einfluss auf immunparameter, lebensqualität und verträglichkeit

Forschende Komplementarmedizin

Volumn 15, Issue 1, 2008, Pages 22-30

  Loewe Mesch, A ^a   Kuehn, J J ^c   Borho, K ^a   Abel, U ^b   Bauer, C ^b   Gerhard, I ^a   Schneeweiss, A ^a   Sohn, C ^a   Strowitzki, T ^a   V Hagens, C ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Lukasklinik Arlesheim   (Switzerland)

Author keywords

Breast cancer; Chemotherapy; Immune parameters; Mistletoe therapy; Quality of life

Indexed keywords

GLUCOCORTICOID; VISCUM ALBUM EXTRACT;

ADULT; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL SUBPOPULATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HEMATOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PROSPECTIVE STUDY; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; THROMBOCYTE; VISCUM ALBUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; COMPLEMENTARY THERAPIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; PLANT PREPARATIONS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 40549090910     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000112860     Document Type: Article

References (40)

1. Grothey A, Düppe J, Hasenburg A, Voigtmann R: Use of alternative medicine in oncology patients. Dtsch Med Wochenschr 1998;123:923-929.
2. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: A systematic review. Cancer 1998;83:777-782.
3. Munstedt K, Entezami A, Kullmer U: Oncologic mistletoe therapy: Physicians use and estimation of efficiency. Dtsch Med Wochenschr 2000;125:1222-6.
4. Jacobson JS, Workman SB, Kronenberg F: Research on CAM for patients with breast cancer: A review of the biomedical literature. J Clin Oncology 2000;18:668-83.
5. Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D: Alternative therapies used by woman with breast cancer in four ethnic populations. J Natl Cancer Inst 2000;92:42-47.
6. Sehouli J, David M, Kaufmann B, Lichtenegger W: Use of alternative treatments by patients after surgery for gynecologic malignancies. Ger J Obstet Gynecol 2000;60:147-154.
7. Schonekaes K, Micke O, Mucke R, Buntzel J, Glatzel M, Bruns F, Kisters K: [Use of complementary/alternative therapy methods by patients with breast cancer]. Forsch Komplementarmed Klass Naturheilkd 2003;10:304-8.
8. Maldacker J: Preclinical investigations with mistletoe (Viscum album L.) extract Iscador. Arzneimittelforschung 2006;56(6A):497-507.
9. Beuth J, Ko HL, Gabius HJ, Burricher H, Oette K, Pulverer G: Behaviour of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Invest 1992;70:658-661.
10. Beuth J, Stoffel B, Ko HL, Buss G, Tunggal L, Pulverer G: Immunoactive effects of various ML-I dosages in mammary cancer patient. Arzneimittelforschung 1995;45:505-507.
11. Heiny BM, Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 1994;14:1339-1342.
12. Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 1998;18:583-586.
13. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004;24(1):303-9.
14. Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U: The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2004;24(2C):1293-302.
15. Semiglasov VF, Stepula VV, Dudov A, Schnitker J, Mengs U: Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006:26(2B):1519-29.
16. Heiny BM: Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin 1991:12:1-14.
17. Mansky PJ: Mistletoe and cancer: controversies and perspectives. Semin Oncol 2002;29(6):589-94.
18. Schumacher K, Schneider B, Reich G, Stiefel T, Stoll G, Bock PR, Hanisch J, Beuth J: Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res 2003;23(6D):5081-7.
19. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B: [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung 2004;54(8):456-66. Erratum in Arzneimittelforschung 2004;54(9):563.
20. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiß A, Strutz J, Hennig M, Lenartz T, Arnold W: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomized controlled clinical trial. Eur J Cancer 2001;37:23-31.
21. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM: EORTC Melanoma Group in cooperation with the German Cancer Society (DKG): Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40(3):390-402.
22. Ernst E, Schmidt K, Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107(2):262-7.
23. Kienle GS, Berrino F, Büssing A, Portulapi E, Rosenzweig S, Kiene H: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 2003;8:109-119.
24. Gerhard I, Abel U, Loewe-Mesch A, Huppmann S, Kuehn JJ: Problematik randomisierter Studien in der Komplementärmedizin dargestellt am Beispiel der Misteltherapie bei Patientinnen mit Mammakarzinom. Forsch Komplementärmed 2004;11:150-157.
25. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleischman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F: The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
26. Abel U, Bauer C: Forschungsberichte der Abteilung Medizinische Biometrie, Universität Heidelberg, Nr. 40, Juni 2002.
27. Lenartz D, Stoffel B, Menzel J, Beuth J: Immunoprotective activity of the galactoside-specific lectin from Mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 1996;16:3799-3802.
28. 〉 M) bei Patientinnen mit Mammakarzinom; in Kropiunigg U, Stacher A (eds): Ganzheitsmedizin und Psycho-Neuroimmunologie. Vierter Wiener Dialog. Wien, Facultas, 1997, pp 396-407.
29. Huber R, Rostock M, Goedl R, Lüdtke R, Urech K, Klein R: Immunologic effects of mistletoe lectins: a placebo-controlled study in healthy subjects. J Soc Integr Oncol 2006;4(1):3-7.
30. Büssing A, Rosenberger A, Stumpf C, Schietzel M: Lymphocyte subsets in tumor patients during subcutaneous mistletoe therapy. Forsch Komplementärmed 1999;6:196-204.
31. Smith RE: Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Canc Netw 2006;4(7):649-58.
32. Ferguson LR, Philpott M: Cancer prevention by dietary bioactive components that target the immune response. Curr Cancer Drug Targets 2007;7(5):459-64
33. Yuvaraj S, Premkumar VG, Vijaysarathy K, Gangadaran SG, Sachdanandam P: Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q(10), Niacin and Riboflavin. Cancer Chemother Pharmacol 2007, DOI 10.1007/s00280-007-0547-z.
34. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007;297(8):842-57.
35. Herr I, Marme A: Glucocorticoids and progression of breast cancer. Cancer Biol Ther 2005;4(12):1415-6.
36. Herr I, Pfitzenmaier J: Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 2006;7(5):425-30.
37. Schuld A, Birkmann S, Beitinger P, Haack M, Kraus T, Dalal MA, Holsboer F, Pollmacher T: Low doses of dexamethason affect immune parameters in the absence of immunological stimulation. Exp Clin Endocrinol Diabetes 2006;114(6):322-8.
38. Steuer-Vogt M, Bonkowsky V, Scholz M, Fauser C, Licht K, Ambrosch P: Einfluss eines ML-1-normierten Mistelextraktes auf die Lebensqualität bei Patienten mit Kopf-Hals-Karzinomen. HNO 2006;54:277-286.
39. Deutschinoff G, Friedrich C, Thiem U, Voigtmann R, Pientka L: Lebensqualität in der Onkologie. Status Quo und Ausblick. Onkologe 2005;11:164-172.
40. Johnson JR, Temple R: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985;69 (19):1155-1159.